5-bromo-6-ethylisoquinoline | 679433-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-bromo-6-ethylisoquinoline
• 英文别名: Isoquinoline, 5-bromo-6-ethyl-
• CAS: 679433-93-3
• 化学式: C₁₁H₁₀BrN
• 分子量: 236.111
• InChiKey: LUBLWXXDXUAREB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-bromo-6-ethylisoquinoline 在 三乙基硅烷 、 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 5-(5-Bromo-benzo[1,3]dioxol-4-ylmethyl)-6-ethyl-isoquinoline
  参考文献：
  名称：

  Synthesis and SAR exploration of dinapsoline analogues

  摘要：

  Dinapsoline is a full D-1 dopamine receptor agonist that produces robust otational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D-1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D-1 and D-2 receptors was decreased by most substituents on the A, B', and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.11.015
• 作为产物：
  描述：

  6-ethylisoquinoline 在 aluminum (III) chloride 、 溴 作用下， 以26 %的产率得到5-bromo-6-ethylisoquinoline
  参考文献：
  名称：

  [EN] 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE CYCLOBUTYLE 1,3-SUBSTITUÉS ET LEURS UTILISATIONS

  摘要：

  本文提供了化合物和药物组合物，用于治疗由TRPV1受体介导的疾病或疾病。本发明还提供了通过向需要治疗的受体施用公式（I）的化合物或本文所述的药物组合物的治疗方法，用于治疗眼部疾病或疾病的方法。 (I)

  公开号：

  WO2022201097A1

文献信息

• Synthesis and SAR exploration of dinapsoline analogues
  作者：S Sit

  DOI：10.1016/j.bmc.2003.11.015

  日期：2004.2.15

  Dinapsoline is a full D-1 dopamine receptor agonist that produces robust otational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D-1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D-1 and D-2 receptors was decreased by most substituents on the A, B', and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity. (C) 2003 Elsevier Ltd. All rights reserved.
• [EN] 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE CYCLOBUTYLE 1,3-SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2022201097A1

  公开（公告）日：2022-09-29

  Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein. (I)

  本文提供了化合物和药物组合物，用于治疗由TRPV1受体介导的疾病或疾病。本发明还提供了通过向需要治疗的受体施用公式（I）的化合物或本文所述的药物组合物的治疗方法，用于治疗眼部疾病或疾病的方法。 (I)